Background {#Sec1}
==========

Trauma is one of the leading causes of death among adults around the world \[[@CR1]\]. The most common causes of early death in trauma patients are hemorrhagic shock, cardiopulmonary dysfunction, and severe brain damage. Therefore, controlling active hemorrhages, maintaining arterial oxygenation, and draining pneumothorax or cardiac tamponade are essential techniques in emergency departments to decrease the early mortality rate in trauma patients \[[@CR2], [@CR3]\]. For selected trauma patients who are in advanced shock or respiratory failure, extracorporeal membrane oxygenation (ECMO) can be a salvage therapy that bridges these young and previously healthy patients to recovery \[[@CR4]--[@CR9]\]. ECMO is a simplified version of heart-lung machine that can replace the cardiopulmonary function temporarily; it simply sucks in deoxygenated blood from the patient's venous system and pumps oxygenated blood back to the patient \[[@CR10]\]. Depending on the destination of the oxygenated blood, ECMO offers two operating configurations. Venoarterial (VA) ECMO bypasses the lungs and returns the oxygenated blood back to the aorta. Therefore, VA-ECMO can raise both the arterial pressure and arterial oxygenation. Instead of bypassing the lungs, venovenous (VV) ECMO returns the oxygenated blood back to the right atrium. This arrangement makes the venous blood to be refreshed by ECMO first then by the native lungs. Therefore, VV-ECMO provides a purely respiratory support without significant disturbances to the cardiopulmonary system. According to a recently published meta-analysis that enrolls 215 patients with ECMO-treated post-traumatic respiratory failure, ECMO shows a rescue rate of 50 to 79% and is considered a useful salvage treatment for post-traumatic respiratory failure \[[@CR11]\]. Now ECMO has also become a new attempt to rescue patients with post-traumatic shock and some encouraging experiences are sporadically reported \[[@CR4], [@CR7], [@CR9]\]. However, as an extracorporeal circulation, ECMO requires heparinization and thus carries a risk of hemorrhage \[[@CR10]\]. According to the Extracorporeal Life Support Organization Registry International Report 2016 \[[@CR12]\], the overall incidence of hemorrhage in ECMO-treated adult patients is around 34% (respiratory support) to 43% (cardiac support). The risk of intracranial hemorrhage is around 2--4% in this report. However, the risk of hemorrhage on ECMO should increase while applying this heparin-equipped therapy to patients with a significant trauma-induced coagulopathy (TIC) \[[@CR13], [@CR14]\]. The study was aimed at presenting our experience on ECMO used for post-traumatic cardiopulmonary dysfunctions and identifying the independent predictors of hospital mortality.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

From August 2006 to October 2014, a total of 638 patients received ECMO for hemodynamic (venoarterial mode; *n* = 489) or pulmonary (VV mode; *n* = 159) support at Chang Gung Memorial Hospital. Among the 638 patients, 36 adults (age ≥ 20 years) were enrolled in this retrospective study due to post-traumatic shock or post-traumatic respiratory failure. Before the administration of ECMO, all of the patients had received a whole body CT to recognize the major bleeding sites and received essential procedures (surgery or transarterial embolization) to stop active bleeding. After the major bleeding sites were controlled, ECMO would be used to sustain the hemodynamics or ventilation in selected patients with profound shock (systolic arterial pressure \< 60 mmHg), severe hypoxemia \[PaO~2~/ FiO~2~ ratio \< 70 mmHg under maximal mechanical ventilation (MV)\], or in-hospital cardiac arrest (CA). The institutional review board of our hospital approved the protocol (CGMF IRB no. 201601610B0) and waived the necessity of individual patient consent.

Managements of ECMO {#Sec4}
-------------------

The details of the principles and equipment in our practice of ECMO have been described in previous reports \[[@CR8], [@CR9], [@CR15], [@CR16]\]. According to the candidate's need, the femoral-femoral VA-ECMO (cut-down cannulation) or the femoral-jugular VV-ECMO (percutaneous cannulation) are provided promptly. The ECMO circuit is heparin-bonded and primed with heparin-contained (2500 U/L) normal saline. To balance the thrombotic and hemorrhagic risks on ECMO, two anticoagulant strategies of ECMO are prepared. The heparin- titrated strategy includes a pre-cannulation bolus dose (5000 unit) and a continuous intravenous maintenance dose of heparin to keep a prolonged aPTT (45--55 s) during ECMO. This strategy is applied to patients who develop a need of ECMO after couple days of trauma, since their risk of hemorrhage on ECMO should be similar to general population. In the other hand, the heparin- minimized strategy waives the pre-cannulation dose and delivers the continuous maintenance dose of heparin after 48 h of ECMO. Approaching a near-normal aPTT (\< 40 s) is the therapeutic goal in this period to achieve a satisfactory hemostasis. This strategy is applied to the patients who develop a need of ECMO soon after trauma or damage control interventions, since their risk of hemorrhage on ECMO should be increased due to the effects of Trauma-induced coagulopathy (TIC) \[[@CR14]\]. During ECMO, the dose of vasopressors and the intensity of MV are gradually down-graded to maintain a normal mean arterial pressure (70--90 mmHg) and arterial oxygenation (PaO~2~ \> 60 mmHg, PaCO~2~ 30-50 mmHg, and SaO~2~ \> 90%). Continuous renal replacement therapy (CRRT) is used to maintain negative fluid balance in patients with a temporary renal failure. While signs of recovery are presented, the support of ECMO is tapered and stopped if possible. For patients hemorrhaging on ECMO, withholding heparin plus blood transfusion (RBC: plasma: platelet about 1:1:3) is often the first step to achieve hemostasis on ECMO. Endoscopic, angiographic or surgical hemostasis was launched with low threshold once the conservative treatment failed or is impossible to stabilize the hemorrhage. Protamine or antifibrinolytic agents would be provided to patients in whom an obvious source of hemorrhage is not found after a series of investigations.

Data collection and outcome measures {#Sec5}
------------------------------------

We retrospectively reviewed the electronic medical records in each patient and collected their important demographic and clinical data before and during the administration of ECMO. The following variables were collected: age, gender, characteristics of trauma, injury severity score, damage control interventions,, duration of MV before ECMO, MV settings (peak inspiratory pressure, mean airway pressure, positive end-expiratory pressure, F~i~O~2~), duration of emergency room (ER) admission to ECMO administration, cardiac arrest and requiring ECMO-assisted cardiopulmonary resuscitation (E-CPR), the latest results of blood tests (arterial blood gas sampling, blood cell counts, creatinine, and total bilirubin) before ECMO, aPTT values before ECMO and during the first, 12th, 24th and 48th hour of ECMO, durations of hospital and ECMO stay, complications (hemorrhage, requiring CRRT, and brain events) of ECMO, and the outcome (survived or death in hospital). The brain events on ECMO included brain hemorrhage and brain infarction. The primary endpoint of this study was death in hospital, and the secondary endpoint was hemorrhage during ECMO.

Statistical analysis {#Sec6}
--------------------

Statistical analyses were performed using SPSS for Windows (Version 15.0, SPSS, Inc., IL, USA). Because the dataset was small, the Mann--Whitney *U* test was used to conduct univariate comparisons of the independent variables. The Chi-square or Fisher's exact test was used to compare the categorical variables. The level of statistical significance was set at *p* \<  0 .05. Continuous variables with a *p* \<  0.05 were dichotomized according to the cut-off values. The cut-off values were determined by the receiver operating characteristic curve (ROC) analysis. These dichotomized risk factors were tested by the multivariate logistic regression analysis with backward stepwise selection to identify independent predictors of hospital mortality and hemorrhage on ECMO.

Results {#Sec7}
=======

Univariate comparison {#Sec8}
---------------------

The median age and median ISS of the 36 patients were 36 (27--49) years and 29 (19--45), respectively. Among the 36 patients, 14 received VA-ECMO due to post-traumatic shock and 22 received VV-ECMO due to post-traumatic respiratory failure. In the group of VA-ECMO, eight patients required conventional CPR due to CA before ECMO institution. Three of the 8 patients regained spontaneous circulation after conventional CPR but still received VA-ECMO for the fluctuated hemodynamics. The other 5 patients developed refractory CA and eventually required E-CPR to restore spontaneous circulation. The median ECPR time was 35 (18--55). The causes of CA in the E-CPR group were severe airway obstruction with difficult intubation (*n* = 2), insufficient drainage of tension pneumothoraces/pneumomediastinum (*n* = 1), profound acidemia due to exsanguination during damage control surgery (*n* = 1), and profound sepsis due to intra-abdominal infection (*n* = 1). The patient with insufficient drainage of tension pneumothoraces/pneumomediastinum suffered from blunt chest injury with severe chest wall deformities, bilateral lung contusions, and pneumothoraces. He was treated with MV and bilateral tube thoracostomies initially and prepared for VV-ECMO implantation later due to his clinical deterioration. Unfortunately, he developed CA before the ECMO team arrived and he could just receive E-CPR with VA-ECMO. Twenty-four patients were weaned off ECMO after a median support of 130 (69--249) hours, and 21 of these patients survived to hospital discharge, including the 2 patients undergoing E-CPR. Figure [1](#Fig1){ref-type="fig"} summarizes the clinical features among patients categorized by the need for ECMO (shock or respiratory failure) and the outcome (died or survived). The information on the mechanisms of trauma and associated therapies in each patient is summarized in [Appendices 1](#Sec12){ref-type="sec"} and [2](#Sec13){ref-type="sec"}. Twelve patients experienced major hemorrhage (4 intracranial, 5 intra-thoracic, and 3 intra-abdominal) on ECMO. Three patients were found to have significant brain infarctions. Ten patients experienced acute renal failure on ECMO and required CRRT. Table [1](#Tab1){ref-type="table"} lists the results of univariate comparisons between the survivors and non-survivors. Compared to the survivors, the non- survivors tended to have a higher ISS, post-traumatic shock/CA rather than respiratory failure, and a shorter hospital stay. In the VA-ECMO group, patients requiring E-CPR showed a similar hospital mortality rate when compared with patients receiving VA-ECMO for refractory shock(60% vs.67%; *p* = 1.0). On the other hand, the only significant difference between the hemorrhagic and the non-hemorrhagic groups was the value of aPTT obtained before ECMO (median aPTT: 52 vs. 33 s; *p* = 0.01). Table [2](#Tab2){ref-type="table"} demonstrates the results of univariate comparisons between the patients developing major hemorrhages on ECMO and the patients not. Compared to the non-hemorrhagic patients, the hemorrhagic patients tended to have a longer aPTT before ECMO institution. Figure [2](#Fig2){ref-type="fig"} shows the trends of aPTT on ECMO in the hemorrhagic and non-hemorrhagic groups.Fig. 1The flowchart of case distribution. CRRT: Continuous renal replacement therapy. ECMO: Extracorporeal membrane oxygenation. ER: Emergency room. ISS: Injury severity score. MV: Mechanical ventilation.VA: Venoarterial. VV: VenovenousTable 1Demographic and clinical data between survivors and non-survivorsSurvivor (*n* = 21)Non-survivor (*n* = 15)*P*Pre-ECMO demographic data Age (year)37 (26--51)35 (27--47)0.85 Male19 (90)12 (80)0.63 ISS25 (17--38)41 (25--75)0.03\* Traumatic brain injury1 (5)3 (20)0.29 MV hours14 (6--126)26 (9--50)0.87 Damage control intervention13 (62)10 (67)0.77 ER-to-ECMO hours21 (9--149)37 (14--52)0.75Data obtained just before ECMO pH7.29 (7.10--7.40)7.20 (6.91--7.32)0.14 Mean arterial pressure (mmHg)^a^71 (53--92)50 (44--59)0.01\* PaO~2~ (mmHg)53 (43--67)47 (40--70)0.55 PaCO~2~ (mmHg)45 (39--70)52 (46--87)0.19 PaO~2~/FiO~2~ (mmHg)54 (46--67)49 (40--83)070 Peak inspiratory pressure (cmH~2~O)35 (31--38)36 (32--48)0.21 PEEP (cmH~2~O)20 (15--24)21 (15--24)0.88 Hemoglobin (g/dL)11 (9--14)13 (9--15)0.57 Platelet count (×  10^9^/L)178 (90--199)94 (69--190)0.28 aPTT (second)32 (28--41)40 (35--62)0.04\*Venovenous ECMO16 (76)6 (40)0.03\*ECMO-assisted CPR2 (10)3 (20)0.63Complication on ECMO Major bleeding4 (19)8 (53)0.07 Requiring CRRT3 (14)7 (47)0.06 Brain event4 (19)3 (20)1.0ECMO hour143 (76--219)111 (36--297)0.47Hospital day44 (29--78)10 (5--23)\< 0.001\*Numerical variables are presented as median and interquartile range (IQR). Categorical variables are presented as number (percentage)*aPTT* Activated partial thromboplastin time, *CPR* Cardiopulmonary resuscitation, *CRRT* Continuous renal replacement therapy, *ECMO* Extracorporeal membrane oxygenation, *ER* Emergency room, *ISS* Injury severity score, *MV hour* Mechanical ventilation hours before ECMO, *PEEP* Positive end-expiratory pressure, *Brain event* Brain hemorrhage or infarction^a^Exclude patients with refractory cardiac arrest and requiring ECMO-assisted CPR\*: *p* \<  0.05Table 2Demographic and clinical data between the patients developing major hemorrhages on extracorporeal membrane oxygenation and the patients notHemorrhagic patient (*n* = 12)Non-hemorrhagic patient (*n* = 24)*P*Pre-ECMO demographic data Age (year)34 (25--52)37 (27--49)0.86 Male9 (75)22 (92)0.31 ISS33 (19--75)29 (19--43)0.54 Traumatic brain injury2 (17)2 (8)0.59 MV hours15 (5--44)33 (8--139)0.28 Damage control intervention9 (75)14 (58)0.47 ER-to-ECMO hours17 (6--42)48 (12--166)0.053Data obtained just before ECMO pH7.26 (7.13--7.34)7.20 (7.09--7.37)0.80 Mean arterial pressure (mmHg)^a^54 (35--66)64 (50--86)0.16 PaO~2~ (mmHg)48 (42--66)52 (40--68)0.88 PaCO~2~ (mmHg)50 (39--70)52 (39--72)0.78 PaO~2~/FiO~2~(mmHg)48 (42--66)49 (40--83)0.61 Peak inspiratory pressure (cmH~2~O)35 (32--40)35 (31--39)0.88 PEEP (cmH~2~O)22 (14--25)19 (15--24)0.75 Hemoglobin (g/dL)12 (10--15)11 (9--15)0.61 Platelet count (× 10^9^/L)93 (73--164)171 (89--220)0.07 aPTT (second)52 (36--100)33 (29--39)0.01\*Venovenous ECMO7 (58)15 (63)1.0ECMO-assisted CPR2 (17)3 (13)1.0Complication on ECMO Requiring CRRT4 (33)6 (25)0.70 Brain event2 (17)5 (21)0.03\*ECMO hour101 (45--248)152 (71--271)0.40Hospital day15 (6--50)40 (24--51)0.21Numerical variables are presented as median and interquartile range (IQR). Categorical variables are presented as number (percentage)*aPTT* Activated partial thromboplastin time, *CPR* Cardiopulmonary resuscitation, *CRRT* Continuous renal replacement therapy, *ECMO* Extracorporeal membrane oxygenation, *ER* Emergency room, *ISS* Injury severity score, *MV hour* Mechanical ventilation hours before ECMO, *PEEP* Positive end-expiratory pressure, *Brain event* Brain hemorrhage or infarction^a^Exclude patients with refractory cardiac arrest and requiring ECMO-assisted CPR\*: *p* \<  0.05Fig. 2The time courses of the activated partial thromboplastin time during the first 48 h of extracorporeal membrane oxygenation. Median with 25th to 75th interquatile range. \* The upper limit of detectable value of aPTT is 120 s

Multivariate comparison {#Sec9}
-----------------------

Before entering the multivariate test, the ISS was dichotomized at the point of 35 according to the results of ROC analysis. The sensitivity (Sn), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV) at this cut-off point for predicting hospital mortality were 67%, 76%, 67%, and 76%, respectively. With the same processing, the aPTT obtained before ECMO was also dichotomized at the point of 40. The Sn, Sp, PPV, and NPV at this cut-off point for predicting hemorrhage on ECMO were 67%, 67%, 59%, and 74%, respectively. Finally, an ISS \> 35 and the requirement of VA-ECMO due to a refractory post-traumatic shock/CA were identified to be the independent predictors of hospital mortality of the ECMO-treated trauma patients. With the same method, a pre-ECMO value of aPTT \> 40 s was proved to be the independent predictor of hemorrhage on ECMO. The indicators of diagnostic accuracy at this cutoff point were 67% (Sn), 79% (Sp), 62% (PPV), and 83% (NPV), respectively. Table [3](#Tab3){ref-type="table"} demonstrates the results of multivariate analysis. Table [4](#Tab4){ref-type="table"} presents the observed and predicted hospital mortalities calculated by the multivariate logistic regression model.Table 3Results of multivariate analysisEndpointPredictorβ coefficientOdds Ratio (95% CI)*p* value^a^Hospital DeathISS \> 351.9056.716 (1.359--33.187)0.019Shock/Cardiac arrest1.6255.079 (1.012--25.499)0.048^b^Hemorrhage on ECMOPre-ECMO aPTT \> 40 s2.0287.6 (1.609--35. 906)0.01^a^Predicted mortality (y) = ℮^X^ / (1 + ℮^X^). X = − 1.853 + 1.905 × (Injury severity score \> 35) + 1.625 × (post-traumatic shock or cardiac arrest). Hosmer-Lemeshow test *p* = 0.985; Negelkerke R^2^ = 0.354; c-index = 0.79^b^Predicted risk of hemorrhage on ECMO (y) = ℮^X^ / (1 + ℮^X^). X = − 1.558 + 2.028 × (Pre-ECMO aPTT \> 40 s)Negelkerke R^2^ = 0.253; c-index = 0.73Table 4The observed and predicted hospital mortalities in the patient cohortClass IClass IIClass IIIClass IVIndication of ECMORespiratory failure (ISS ≤ 35)Shock/CA (ISS ≤ 35)Respiratory failure (ISS \> 35)Shock/CA (ISS \> 35)Total Number14787Death Number2346Observed Mortality14.3%42.9%50%85.7%Predicted Mortality^a^13.5%44.3%51.3%84.2%^a^Predicted mortality: (y) = ℮^X^ / (1 + ℮^X^). X = − 1.853 + 1.905 × (Injury severity score \> 35) + 1.625 × (Shock/CA requiring VA-ECMO)Table 5Reports focused on extracorporeal membrane oxygenation used in patients presenting traumatic brain injuryAuthor\
(Country; Year)Therapeutic\
purposeSeverity of TBICase Number;\
Median age (y)/ ISSDevice\
/ER-to-device timeAnticoagulation/\
Hemorrhagic eventMortality/\
Median Device TimeReynolds\[19\]\
(USA/1999)Ventilation assistanceTBI (AIS 3)\
ICP monitor: No1 case;\
16/18VV-ECMO\
/0 (d)Heparin free/\
Pulmonary hemorrhageNo\
/7 (d)Yen \[20\]\
(Taiwan/2008)Hemodynamic assistanceTBI (AIS 5)\
ICP monitor: Yes1 case;\
21/NA\*VA-ECMO\
/2 (d)Heparin free/\
No hemorrhagic eventNo\
/49 hoursMessing \[21\]\
(USA/2014)Ventilation assistanceTBI (AIS ≥ 3)\
ICP monitor: Yes1 case;\
21/38VV-ECMO\
/3 (d)Initial heparin free then ACT 180-200 s/\
No hemorrhagic eventNo\
/20 (d)Muellenbach \[22\]\
(Germany/2012)Ventilation assistanceTBI (AIS ≥ 3)\
ICP monitor: Yes3 cases;\
53/59, 16/66, 28/66VV-ECMO\
/2 (d), 0 (d), 0(d)Initial heparin free then aPTT 40-60 s/\
No hemorrhagic eventNo\
/8 (d), 3 (d), 3(d)Munoz-Bendix \[23\]\
(Germany/2015)Reducing PaCO~2~ for ICP reductionTBI (AIS \>3)\
ICP monitor: Yes10 cases;\
50 /NA\*pECLA\
/ 6(d)aPTT 50-60 s/\
NA\*NA\*\
/8 (d)Biscotti \[24\]\
(USA/2015)Ventilation assistanceTBI (AIS \>3),\
ICP monitor: Yes2 cases;\
18/27, 20/33VV-ECMO\
/4 (d), 4(d)aPTT 40-60 s/\
No hemorrhagic eventNo\
/ 6(d), 13 (d)Zhou \[25\]\
(China/2015)Ventilation assistance\
during tracheal repairTBI (AIS 3),\
ICP monitor: No1 case;\
33/34VA-ECMO\
/4 (d)ACT 300 (s)/\
No hemorrhagic eventNo\
/551 minutesRobba \[26\]\
(UK/2017)Ventilation assistanceTBI (AIS ≥ 3)\
ICP monitor: Yes2 cases;\
31/41, 54/32VV-ECMO\
/5 (d), 20 (d)NA\*/\
No hemorrhagic event50% (n=1)\
/20 (d), 4 (d)*ACT:* Active clotting time. *APTT:* Activated partial thromboplastin time. *ECMO*: Extracorporeal membrane oxygenation. *ICP*: Intracranial pressure monitor. *pECLA*: Pumpless extracorporeal lung assist. *TBI*: Traumatic brain injury. *VA*: Venoarterial. *VV*: Venovenous\*NA: Not available

Discussion {#Sec10}
==========

This study is aimed at identifying the independent predictors of hospital mortality in adult trauma patients receiving ECMO for advanced cardiopulmonary dysfunctions. Due to the complicated technique and the high resource demand, ECMO is not a routine therapy for advanced cardiopulmonary dysfunctions. However, after experience accumulation, it can become a valuable salvage treatment for advanced cardiopulmonary dysfunctions induced by various etiologies. Based on our experience of handing the coagulopathy in patients requiring postcardiotomy ECMO support \[[@CR16]\], we considered that all the surgical or trauma candidates must have their major bleeding sites identified and controlled before the delivery of ECMO. This is the most important selection criterion in our practice \[[@CR8], [@CR9]\]. Once ECMO is delivered to a patient with a high risk of hemorrhage, the heparin effect must be minimized even reversed during the support of ECMO \[[@CR8], [@CR9]\]. According to the current study, the mortality rates of the ECMO-treated post-traumatic shock and respiratory failure were 64% and 27%, respectively. Compare to our previous publications, the mortality rate of the ECMO-treated post-traumatic shock here was similar to the mortality rate of the ECMO-treated postcardiotomy shock (64% vs. 58%; *p* = 0.66) \[[@CR16]\]. In the other hand, the mortality rate of the ECMO-treated post-traumatic respiratory failure here was lower than the mortality rate of the ECMO-treated non-traumatic respiratory failure (27% vs. 51%; *p* = 0.05) \[[@CR17]\]. Therefore, we thought that ECMO could be a useful life support for advanced post-traumatic cardiopulmonary dysfunctions with a careful patient selection.

In the current study, an ISS \> 35 and a refractory post-traumatic shock/CA were found to be independent predictors of hospital mortality in these ECMO-treated trauma patients. The two factors may build a simple classification model for this patient population. According to the Table [3](#Tab3){ref-type="table"}, both the observed and predicted hospital mortality rates were over 80% in patients with the two features. A similar result is found while the classification was applied to a published cohort of 18 adult trauma patients who required ECMO support \[[@CR4]\]. Therefore, the patient who has an ISS \> 35 and developing a refractory post-traumatic shock/CA should be a suboptimal candidate for ECMO resuscitation, and the decision of enrolling should be made carefully. On the contrary, ECMO seems to be a promising therapeutic option for advanced post-traumatic respiratory failure. Post-traumatic respiratory failure is a common complication seen in patients with blunt chest trauma. Except for pulmonary contusions and transfusion-induced acute lung injury, there are some specific conditions may hinder the work of MV in trauma patients. These conditions include a significant air leak due to pulmonary lacerations, uncoordinated thoracic cage movements due to complex fractures, and restrictive intra-thoracic spaces due to abdominal compartment syndrome. Once thoracotomy is required for hemorrhage control, the associated one-lung ventilation may also bring additional volutrauma to the lungs and increase the risk of advanced respiratory failure after operation. Some of these injuries require surgical repairs but some are improved with lung rest and negative fluid balance. All these can be safely managed by an experienced ECMO team with multidisciplinary expertise \[[@CR6], [@CR8]\]. Therefore, if the major bleeding sites are controlled, VV-ECMO is indeed a valuable option to assist these young and previously healthy adults to conquer the temporary respiratory failure and survive.

In this study, twelve of the ECMO-treated trauma patients developed major hemorrhages on ECMO. Nine of the 12 hemorrhagic patients had a prolonged aPTT (\> 40 s) before the administration of ECMO. As shown in Fig. [2](#Fig2){ref-type="fig"}, ECMO induces an abrupt rise of aPTT in all patients, including the patients treated with the heparin-minimized strategy. Patients with a prolonged aPTT before ECMO institution are quite vulnerable to the anticoagulation effects of heparin and might still lose blood from the oozing wounds due to the difficulty in formatting steady blood clots on ECMO, although the major bleeding sites had been controlled. Reversing the heparin with protamine, mitigating the consumption coagulopathy with blood transfusion, stabilizing the formed blood clots with antifibrinolytic agents, and allowing permissive hypotension are common strategies used to maintain an acceptable output of ECMO before hemostasis is achieved. However, permissive hypotension may inevitably prolong the period of hypoperfusion and jeopardize the survival rate. Therefore, the scale and duration of this hypocoagulation period should be a critical target for intervention while using ECMO to rescue patients with significant TIC. Despite not used in our practice yet, the viscoelastic assay is another valuable technique of coagulation monitoring in this scenario \[[@CR3], [@CR18]\].

Regardless of the indications, applying ECMO to patients with traumatic brain injury (TBI) is still a controversial issue. In the current study, four patients developed major ICHs on ECMO. One patient had a re-bleeding TBI, and 3 patients had newly developed ICHs. All of them received ECMO soon after admission, with a median ER-to-ECMO time of 11 h. In the other hand, the TBIs did not re-bleed in the other 3 patients who had a longer ER-to-ECMO time (47, 248 and 295 h, respectively). Therefore, the ER-to-ECMO time seemed to have an effect on re-bleeding from TBIs during ECMO, although a heparin-minimized strategy was adopted. Due to the small sample size, it is impossible to draw any definite conclusion to document the feasibility of delivering ECMO to patients with known TBI. To shorten this knowledge gap, we decided to perform a simple literature review of the case reports focusing on applying ECMO or similar device to patients with TBI. We collected eight English publications from PubMed that were published from 1999 to 2017 \[[@CR19]--[@CR26]\]. The eight studies, enrolling 21 patients with known TBI before ECMO, are summarized in Table [5](#Tab5){ref-type="table"}. The therapeutic purpose is ventilation assistance in seven of the eight studies. The severity of TBI is significant in 19 patients in whom an extraventricular drainage is placed for intracranial decompression and pressure monitoring. Most of the patients have an ER-to-device time \> 2 days, and a heparin-free ECMO is provided to patients with an ER-to-device time \< 3 days. No TBI re-bleeding occurs, and just one hospital death is reported. According to the above-mentioned findings, ECMO with a heparin-free strategy seems to be safe in patients with minor or drained TBI. However, the summary could be more comprehensive if the therapeutic ranges of aPTT of the "heparin-free" ECMO are available.

The limitations of this study are its retrospective design and the small number of cases involved. The observations were obtained from the ECMO-treated patients only and all of the patients were highly selected by the ECMO team. Further prospective or large-scale retrospective studies are needed to demonstrate the efficacy and safety of ECMO used for post-traumatic cardiopulmonary failure.

Conclusion {#Sec11}
==========

The severity of trauma and the type of cardiopulmonary dysfunction significantly affected the outcomes of ECMO used for sustaining adult patients with post-traumatic cardiopulmonary dysfunction. According to our results, ECMO could be a useful salvage therapy for adult patients with post-traumatic cardiopulmonary dysfunctions if they had an ISS less than 35. Hemorrhage on ECMO remained a true concern while the device was required soon after trauma, although a heparin-minimized protocol was adopted.

Appendix 1 {#Sec12}
==========

Table 6Summary of major injuries in all patientsCaseISSMajor InjuryVA110Right HxTx. Scalp lacerations.VA213Right HxTx. Grade 2 hepatic injury.VA3413rd degree burn (TBSA35%). Left flail chest with open PnTx. Right femoral bone fracture.VA475Cardiac arrest. Pelvic crush injury with hemorrhagic shock. Bilateral lung contusions.VA575Cardiac arrest. Interstitial pulmonary edema.VA6252--3 degree burn (TBSA50%).VA736Left HxPnTx. Cerebral contusions with coma \> 6 h. Minor pelvic fracture.VA825Blunt cardiac injury with left anterior descending artery disruption.VA9162--3 degree burn (face involved; TBSA 10%) and inhalation injury.VA1043Grade 5 splenic lacerations and grade 2 renal lacerations. Right small ICH. Minor facial bone fracture.VA1150Pelvic crush injury with hemorrhagic shock. Grade 4 splenic and grade 3 hepatic lacerations. Diaphragmatic rupture. Bilateral HxPnTx with lung contusions. Traumatic SAH.VA1220Right HxPnTx with lung contusion. Right humeral and left tibial fractures.VA1338Pelvic crush injury with hemorrhagic shock. Right HxPnTx. Right tibia fracture.VA1418Right lung contusion. Mesentery vascular injury. Minor L-spine fracture.VV120Left flail chest with open PnTx. L-spine minor fracture.VV217Bilateral lung contusions. Scalp lacerations.VV329Bilateral HxPnTx with multiple ribs fracture. C-Spine minor fracture.VV434Bilateral lung contusions. Grade 3 hepatic lacerations. LeFort I facial and right femoral bone fracture.VV575Cardiac arrest. Blunt cardiac injury with large hemopericardium.VV675Cardiac arrest. Bilateral lung contusions. Grade 4 hepatic lacerations.VV792--3 degree burn (face involved; TBSA 8%) and inhalation injury.VV841Pelvic crush injury with hemorrhagic shock. Left flail chest with lung contusion. Left femoral bone fracture.VV929Bilateral lung contusions with HxTx. Right femoral bone fracture. L-spine minor fracture.VV1075Cardiac arrest. Grade 4 hepatic lacerations.VV1175Cardiac arrest. Pelvic crush injury with hemorrhagic shock. Mesenteric vascular injury. Urinary bladder disruption. Multiple ribs fractures with right HxTx.VV1222Right HxPnTx. Stomach and diaphragmatic perforation. Head concussion.VV1343Blunt cardiac injury with cardiac rupture. Facial bone and skull base fractures with pneumocranium and SAH. Mesenteric injury. Small bowel disruption.VV1425Blunt injury of urinary bladder with bladder disruption. Bilateral femoral bone fractures.VV1534Bilateral flail chest with left HxPnTx. Left femoral bone fracture.VV1629Bilateral HxPnTx. Right proximal femoral bone fracture. L-spine minor fracture.VV1745Blunt injury of thoracic aorta with pseudoaneurysm formation. Pelvic crush injury with hemorrhagic shock. Grade 4 hepatic lacerations and mesenteric vascular injury. Minor facial bone fracture.VV1818Skull base fracture. Left HxPnTx.VV1910Traumatic SAH. Minor facial lacerations.VV2017Left renal grade 4 lacerations. Left 11th rib fracture.VV2125Bilateral HxPnTx and lung contusions. Grade 3 liver lacerations.VV2250Blunt injury of thoracic aorta with pseudoaneurysm formation. Grade 5 hepatic lacerations.*HxTx* Hemothorax, *PnTx* Pneumothorax, *HxPnTx* Hemopneumothorax, *ICH* Intracranial hemorrhage, *SAH* subarachnoid hemorrhage

Appendix 2 {#Sec13}
==========

Table 7Patient informationNOAge (year)Trauma MechanismISSER-to-ECMO hourPre-ECMO managementOutcome (ECMO hour)MV hourDamage control surgery/TAEVA-ECMO for post-traumatic shock137Stabbing1043[Thoracotomy]{.ul}: lung wedge resectionSurvived (112)248Traffic accident (car)13413[Thoracotomy]{.ul}: CardiorrhaphySurvived (91)329Electrocution4161NoDead (17)417Traffic accident (car)7562[TAE]{.ul} for retroperitoneal hemorrhage\
External fixation of pelvic fractureDead (216)525Near-drowning7582NoSurvived (384)642Burn25106NoDead (36)733Falling362016[Thoracotomy]{.ul}: RLL and LLL lobectomyDead (297)820Traffic accident (car)252410[Sternotomy]{.ul}: CABG for LAD disruptionSurvived (216)961Burn and inhalation162626NoDead (212)1035Traffic accident (car)433736[Laparatomy]{.ul}: Splenectomy [and pancreatic tail resection]{.ul}Dead (23)1147Traffic accident (car)504750[Thoracotomy]{.ul}: RLL Wedge resection\
[Laparotomy]{.ul}: Diaphragmatic repair, splenectomy, hepatorrhaphy and retroperitoneal packingDead (69)1245Traffic accident (car)204846NoDead (258)1340Falling384860TAE for retroperitoneal hemorrhage\
External fixation of pelvic fractureDead (43)1424Traffic accident (motorbike)18315288[Laparotomy]{.ul}: Small bowel resection\
with end-ileostomySurvive(116)VV-ECMO for post-traumatic respiratory failure153Traffic accident (pedestrian)2054NoSurvived (69)229Traffic accident (motorbike)1776NoSurvived (61)333Traffic accident (motorbike)2995[Thoracotomy]{.ul}: RML-RLL bilobectomy, pericardiotomySurvived (187)433Traffic accident (car)34108NoSurvived (70)559Traffic accident (car)75119[Subxiphoid drainage]{.ul}Survived (75)623Falling75149[Thoracotomy]{.ul}: Repair RML/RLL lacerations\
[Laparotomy]{.ul}: Ligation of right hepatic artery with perihepatic packingDead (40)749Burn and inhalation91618NoSurvived (177)849Traffic accident (pedestrian)411614[TAE]{.ul} for retroperitoneal hemorrhage, external fixation of pelvic fractureSurvived (222)943Traffic accident (motorbike)29214NoSurvived (77)1020Traffic accident (motorbike)752321[TAE]{.ul} for grade 4 hepatic laceration.\
[Laparotomy]{.ul}: Ligation of right hepatic artery and right portal vein with perihepatic packingDead (24)1157Traffic accident (car)755249[TAE]{.ul} for retroperitoneal hemorrhage, external fixation of pelvic fracture.\
[Laparotomy]{.ul}: Resect terminal ileum and right colon with end-ileostomy for bowel perforationDead (423)1237Falling227674[Laparotomy]{.ul}: Repair gastric and diaphragmatic perforation, repair spleen avulsionSurvived (66)1361Traffic accident (motorbike)4310091[Laparotomy]{.ul}: Repair small bowel perforationSurvived (143)1427Compression injury2511540[Laparotomy]{.ul}: CystorrhaphySurvived (161)1525Traffic accident (car)34123108NoSurvived (287)1632Traffic accident (motorbike)29138126NoDead (1030)1728Traffic accident (car)45175143[TAE]{.ul} for grade 3 hepatic laceration\
[Laparotomy]{.ul}: Repair mesocolonic lacerationSurvived (94)1872Traffic accident (motorbike)18248227[Thoracoscopy]{.ul} for empyema evacuationDead (111)1956Traffic accident (motorbike)10295150NoSurvived (517)2058Falling17334310[TAE]{.ul} for grade 4 renal lacerationSurvived (169)2125Traffic accident (pedestrian)25384365[TAE]{.ul} for grade 3 hepatic laceration\
[Thoracotomy]{.ul}: RML-RLL bilobectomy and bronchoplasty\
Exploratory LaparotomySurvived (456)2227Traffic accident (motorbike)50574174[TAE]{.ul} for grade 5 hepatic laceration\
[Laparoscopy]{.ul} for persistent bile leak and intra-abdominal abscess\
[Thoracotomy]{.ul}: Descending aortic replacementDead (352)*CABG* Coronary artery bypass grafting, *CA* Cardiac arrest, *ECMO* Extracorporeal membrane oxygenation, *ER* Emergency room. *ISS* Injury severity score, *LAD* Left anterior descending, *MV hour* Mechanical ventilation hours before ECMO, *TAE* Transcatheter arterial embolization, *RML* Right middle lobe of lung, *RLL*: Right lower lobe of lung

APTT

:   Activated partial thromboplastin time

CA

:   Cardiac arrest

CRRT

:   Continuous renal replacement therapy

ECMO

:   Extracorporeal membrane oxygenation

ER

:   Emergency room

FiO2

:   Fraction of inspiratory oxygen

ICH

:   Intracranial hemorrhage

ISS

:   Injury severity score

MV

:   Mechanical ventilation

PaCO~2~

:   Arterial carbon dioxide tension

PaO~2~

:   Arterial oxygen tension

ROC

:   Receiver operating characteristic

SaO~2~

:   Arterial oxygen saturation

SpO~2~

:   Oxyhemoglobin saturation by pulse oximetry

TBI

:   Traumatic brain injury

TIC

:   Trauma induced coagulopathy

VA

:   Venoarterial

VV

:   Venovenous
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